Optimising Anti-TNF Treatment Using Biosimilars
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
Expert opinion
Learn expert insights on optimising anti-TNF treatment
Biosimilars in clinical practice
Biosimilars can benefit outcomes across many diseases
Biosimilar efficacy & safety
Biosimilar efficacy and safety data is summarised
Practical advice on use of biosimilars
Clinical advice on biosimilars in Crohn’s disease and ulcerative colitis
Making decisions about anti-TNF biosimilars
Shared-decision making for improved adherence
The future of immunology biosimilars
Future treatment targets and what’s next for biosimilars
Congress Highlights
Clinical data on biosimilar treatments from ACR 2022 & more
of interest
are looking at
saved
next event
This content has been developed independently by Medthority who previously received educational funding from Biogen in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.